OCA
ALLO icon

Octagon Capital Advisors’s Allogene Therapeutics ALLO Stock Holding History

Octagon Capital Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-720,000
Closed -$3.22M – 47
2024
Q1 		$3.22M Buy
+720,000
New +$3M 0.39% 46

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Octagon Capital Advisors's ALLO Position: Q2 2024 in Review

Octagon Capital Advisors sold out of Allogene Therapeutics (ALLO) in Q2 2024, closing a stake of 720,000 shares — an estimated $3.22M sold.

Octagon Capital Advisors first reported a position in ALLO in Q1 2024 and held it in 1 quarter. The position peaked at $3.22M in Q1 2024. 174 funds tracked by Wall St. Rank hold ALLO as of Q2 2024.

  • Octagon Capital Advisors reported no remaining Allogene Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 720,000 Allogene Therapeutics shares in Q2 2024, an estimated $3.22M.
  • Octagon Capital Advisors first reported a position in Allogene Therapeutics in Q1 2024 and held it in 1 quarter.
  • Octagon Capital Advisors's Allogene Therapeutics position peaked at $3.22M in Q1 2024.
  • 174 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2024.

Based on Octagon Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.